Cue Biopharma (CUE) Operating Income (2017 - 2025)
Cue Biopharma (CUE) posted Operating Income of $2.0 million for Q4 2025, up 126.04% sequentially from -$7.6 million in Q3 2025, and up 120.53% YoY from $896915.6 in Q4 2024.
Cue Biopharma (CUE) Operating Income (2017 - 2025) Analysis & Trends
Cue Biopharma has reported Operating Income for 9 years, with the latest figure at $2.0 million in Q4 2025.
- Quarterly Operating Income rose 120.53% year-over-year to $2.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$26.6 million (up 36.02% YoY) and the FY2025 annual result came in at -$26.6 million, up 36.02% from the prior year.
- Operating Income rose to $2.0 million in Q4 2025 per CUE's latest filing, from -$7.6 million in the prior quarter.
- Over five years, Operating Income peaked at $2.0 million in Q4 2025 and troughed at -$14.9 million in Q4 2022.
- A 5-year average of -$10.9 million and a median of -$11.9 million in 2023 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income plunged 88.34% in 2022, then jumped 120.53% in 2025.
- Over 5 years, Operating Income stood at -$7.9 million in 2021, then slumped by 88.34% to -$14.9 million in 2022, then gained by 6.96% to -$13.8 million in 2023, then soared by 30.36% to -$9.6 million in 2024, then surged by 120.53% to $2.0 million in 2025.
- According to Business Quant data, Operating Income over the past three periods registered $2.0 million, -$7.6 million, and -$8.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Cue Biopharma | 152.56 Mn | 135.14 Mn | - | -87.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 1.98 Mn |
| Sep 30, 2025 | -7.60 Mn |
| Jun 30, 2025 | -8.64 Mn |
| Mar 31, 2025 | -12.30 Mn |
| Dec 31, 2024 | -9.63 Mn |
| Sep 30, 2024 | -8.82 Mn |
| Jun 30, 2024 | -10.38 Mn |
| Mar 31, 2024 | -12.67 Mn |
| Dec 31, 2023 | -13.83 Mn |
| Sep 30, 2023 | -11.42 Mn |
| Jun 30, 2023 | -13.52 Mn |
| Mar 31, 2023 | -13.38 Mn |
| Dec 31, 2022 | -14.87 Mn |
| Sep 30, 2022 | -11.03 Mn |
| Jun 30, 2022 | -13.09 Mn |
| Mar 31, 2022 | -14.24 Mn |
| Dec 31, 2021 | -7.89 Mn |
| Sep 30, 2021 | -13.02 Mn |
| Jun 30, 2021 | -10.30 Mn |
| Mar 31, 2021 | -12.52 Mn |